{"id":"topical-beremagene-geperpavec","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin blistering"},{"rate":null,"effect":"Skin rash"},{"rate":null,"effect":"Skin redness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The gene therapy uses a viral vector to deliver a copy of the human COL7A1 gene to the skin, which then produces the protein collagen VII. This protein is essential for the formation of anchoring fibrils, which hold the epidermis to the dermis. In patients with dystrophic epidermolysis bullosa, the COL7A1 gene is mutated, leading to a deficiency of collagen VII and the characteristic skin blistering.","oneSentence":"Beremagene geperpavec is a gene therapy that uses a viral vector to deliver a gene to the skin, which then produces a protein to treat the condition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:20.228Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dystrophic epidermolysis bullosa"}]},"trialDetails":[{"nctId":"NCT04917874","phase":"PHASE3","title":"A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Krystal Biotech, Inc.","startDate":"2021-05-25","conditions":"Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa","enrollment":47},{"nctId":"NCT04491604","phase":"PHASE3","title":"Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB","status":"COMPLETED","sponsor":"Krystal Biotech, Inc.","startDate":"2020-08-17","conditions":"Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa","enrollment":31},{"nctId":"NCT03536143","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients","status":"COMPLETED","sponsor":"Krystal Biotech, Inc.","startDate":"2018-05-06","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HSV1-COL7A1","KB103"],"phase":"phase_3","status":"active","brandName":"Topical Beremagene Geperpavec","genericName":"Topical Beremagene Geperpavec","companyName":"Krystal Biotech, Inc.","companyId":"krystal-biotech-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Beremagene geperpavec is a gene therapy that uses a viral vector to deliver a gene to the skin, which then produces a protein to treat the condition. Used for Dystrophic epidermolysis bullosa.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}